Protective effect of pertussis vaccine (PV) against the development of insulin-dependent diabetes (IDD) induced by streptozotocin (STZ) in young CD-1 male mice were studied. When PV at a dose of 1.2 x 101° microorganism was administered on -10, 0, or +4 d relative to a single injection of STZ (60 mg/kg body wt) on d 0, it completely aborted the development of IDD after 140 d. When PV was given on +30 d after STZ injection and followed by PV booster injections, 66% of mice reverted to normoglycemic state. Intact islet cells in the pancreas were confirmed by histologic findings and normal plasma insulin values. The effect of PV was compared with that of boiled PV in another model of IDD induced by multiple injections of STZ (40 mg/kg for five doses). In this model, 60% of mice either remained or reverted to normoglycemic state with PV and booster injections whereas boiled PV protected 40% of mice from developing IDD. The protective effect appeared to reside in the biologic property of both pertussigen and endotoxin of Bordetefla pertussis.
the opportunity for the study of intervention at early stages of the disease which invariably carries high frequency of complication in patients in spite of insulin treatment. Using a single dose STZ model, we previously showed that a prior injection of whole PV before STZ injection would protect susceptible, young CD-1 mice from developing IDD (9) . The protection was confirmed by findings of normal blood glucose level, normal insulin level, normal glucose tolerance test. and the histology of islets in pancreas. In this study, we chose the single dose STZ model and injected PV at various time intervals after STZ injection in order to determine the time course of this protection from IDD. In another experiment, we chose also the multiple dose STZ model to compare the effect of PV vri-sus bPV and to evaluate the role of endotoxin in the protection. Whenever it was indicated, successive booster injection of PV or bPV was employed to assess its effect on established hyperglycemia. This report describes the results of serial blood glucose changes in these groups and histologic findings in islet cells in pancreas in each animal and compare the results with the overall incidence of IDD in each group at the end of the experiment. PV. PV (a gift from Dr. Charles R. Manclark of Bureau of Biologics, FDA, Rockville, MD; Lot 76) in the form of wholecell Bordctella pcrlzlssis vaccine was given at a dose of 0.25 ml containing approximately 1.2 x 101° organisms by intraperitoneal injection. The control animal received 0.25 ml of 0.01 % merthiolate solution which was used as a diluent for the vaccine. bPV was prepared by incubating the reconstituted PV at 80°C for '/I h. This would destroy most of the heat labile biologic factor but would preserve the endotoxin ( 19) .
Blood gllrcosc and in.szllin. The whole blood glucose was mcasured as previously described (17) and the radioimmunoassay of insulin has also been described (9) . t;lsotninufion of'thr pancreas. The mice were exsanguinated under ether anesthesia. The pancreas were removed and immediately fixed for paraffin sectioning in the mixture of 4% formaldehyde and 1% glutaraldehyde in a buffer of 176 mosmol/L (18). After H&E stain. at least 45 islets from different portion of each pancreas were examined for histologic changes compatible with the insulitis or the development of IDD (9) .
E.~~)\;rimcn/ I. Animals were divided into five groups ( n == 6 each). T o each animal STZ was administered at a dose of 60 rng/ kg on d 0. PV was injected on d -10, 0, +4, and +30 relative to STZ injection in four separate groups of mice. The control group received STZ and 0.0 1% merthiolate solution. Serial blood glucose was measured and plasma insulin was assayed at the termination of the experiment. Repeated injections of PV were given to mice that developed hyperglycemia (blood glucose above 200 mg%). The pancreas of each mouse was examined at the end of the experiment.
E,~perim~nt II. In this experiment, STZ was administered daily on 5 successive d at a dose of 40 mg/kg. PV or bPV was injected 3 d before STZ injection in two groups ( n = 10 each). Another group ( n = 10) received 0.01 % merthiolate solution before STZ injection. Control group (n = 6) only received 0.01 % merthiolate solution. Blood glucose was measured serially and booster injection of either PV or bPV was given in respective groups whenever hyperglycemia developed in mice. At the termination of the experiment. histology of pancreas was examined in each mouse.
SILIII'.SI~(~UI .~~I I / J ' s I ' s .
We employed a t test for small samples and chi-square test for the analysis of the data. Figure I illustrates the time course of blood glucose levels of mice injected with a single dose of STZ (60 mg/kg) and with PV which was given at different schedules. The group that received only STZ developed hyperglycemia 4-6 wk after the injection. Thc outcome of the other group of mice receiving PV either before (-10 d). simultaneously (0 d). or after (+4 d ) STZ injection appeared to be the same. All mice that received PV, experienced a hypoglycemic state followed by normoglycemia that lasted for at least 20 wk. In no instance did any of those mice develop hyperglycemia. In the group of mice that received PV when they were already hyperglycemic on d 30 after STZ injection, nornioglyceniia returned and lasted for nearly 8-10 wk before hyperglycemia reappeared in the 12th wk. After a booster dose at that time of PV, four of six mice (66%) in the hyperglycemic group returned to a norrnoglycemic state which lasted more than 6 wk whereas the remaining two mice had developed irreversible hyperglycemia ( Fig. 1) . It thus appeared a timely injection of PV might abort STZ-induced IDD in those experimental conditions.
RESULTS
The plasma insulin values are presented in Table 1 . The control mice which received STZ uniformly developed hypoinsulinemia (15.7 pU/ml) by 30 d after single injection of STZ. Those mice protected by PV all retained normal insulin values. The mice which received STZ developed hypoinsulinemia on d 30 but the injection of PV reversed the plasma insulin values toward normal until the end of the experiment. As previously described, those mice that received STZ uniformly showed a significant decrease in size as well as changes of morphology of islets in pancreas (8. 9) (Fig. 2 ) as compared with controls ( Fig.  3) . Less than 10% of islets in those diabetic mice still showed traces of inflammatory cell infiltrates (Fig. 4) . Those histologic changes were consistently compatible with a significant decrease in their plasma insulin values. each time). A hypoglycemic effect of PV was still noticeable: treated with STL only or control group ( P c 0.05 in either case).
hoxevcr single injection of either PV or bPV failed to protect Repeated booster injections did. however. reverse hyperglycemi;~ effcctivel> the mice f'rom developing byperglycemia in cach in four of cigl~t mice in PV group or in two of eight mice which group (the difference between them was not statistically signifi-received h P V The result of the number of booster injections cant. P > 0 15). although they had significantly lower glucose required and the ~l u~n b c r of mice which returned to normoglylevels at the end oftbe experiment as compared with mice either cemia i;is listed in Table 2 . It appeared that PV was relatively : L Indicates the number of diabetic mice which returned to normoglycemia. () ~nd~catcs the total number of diabetic mice which recci~ed the booster injection.
effective when it was given at the early stage (between 2-6 wk after the onset) of hyperglycemia whereas bPV was only effective at the mid-stage (between 6-9 wk after the onset) of hyperglyceniia. After 8 wk of continued hyperglycemia, neither PV nor bPV would be effective to reverse hyperglycemia (Fig. 5) . (9) . The full protective effect was evidenced by the persistence of normoglycemia. normal results of glucose tolerance tests. normal plasma insulin values. and the lack of appearance of nucleic acid antibodies in the mice immunized with PV (9). Furthermore. there was absence of insulitis in those vaccinated animals as compared with control mice in which inflammation of pancreatic islets were frequently observed (8. 9). The inflammation in the islets is thought to be the primary cause of the permanent damage to D-cells and is an important pathogenetic mechanism leading to the development of IDD.
Our study in Experiment I indicated the anti-diabetogenic effect of PV against STZ was quite extensive. If the vaccine was given from -10 d to +4 d relative to the day of STZ injection. the outcome of the protective effect appeared to be identical. If the PV was given 30 d after STZ which usually would be sufficient to induce hyperglycemia in mice. two-thirds of mice wo~lld still revert to normoglycemia after booster injections. As judged from the plasma insulin values and the histologic findings. it is conceivable that in this model using a single STZ in.jection. the progression of D-cell damage in islets occurs more slowly than the multiple injection model so that interventiolls can be more effective in the former. Usually. the onset of hyperglycemia in this model occurs in : ! wk (13. 14. 22) whereas the former model takes 4-6 wk after STZ injection (8. 16 ). In the multiple dose model employed in Experiment 11, the protection against the de\elopment of hyperglycemia was less complete. After numerous booster injections. the outcome was somewhat improved but was significantly less effective as compared with the results in Experiment I. This suggests that even the simple exposure of the animal to toxin such as STZ was considered subdiabetogenic. a repeated or successive exposure would greatly shorten the latenc! of the development of IDD. This would significantly reduce the optimal time required to practically halt the development of IDD. (20) . Although LPF is known to redistribute circulating lymphocytes and thus modifies lymphocyte activity (1. 7), IAP would act on 8-cells in islets to enhance its insulin release (26). Vv' e confirmed the action of IAP in both Experiment I and I1 as \ve noticed the temporary development of hypoglycemia in immunized mice (Fig. I and 5 ). Currently it is believed that the mechanism of the action of IAP on @-cells in islets appears to be related to its enhancement of adrenergic beta-receptor-mediated process. It seems reasonable. therefore. to speculate that the chain of events timely occurs in 8-cells after the stimulation of IIiP effectively reverses or prevents the damage incurred by STZ. This would explain the fact that the immunization with whole vaccine immediately before the exposure of cell toxin such as STZ may be more effective as illustrated in Table 2 .
By incubating the whole cell PV at 80°C for 30 min. wc were able to distinguish between the effect of the pertussigen and the effect of endotoxin of Rorrle~c~IIu po.tlr.s.si.s. The pertussigen is known to be heat labile. therefore. the remaining effect after the treatment only reflects the biologic effect of endotoxin which is heat stable. This was observed by the lack ofvisible hypoglycemia in mice immediately after the injection of bPV in contrast to the blood glucose change in mice receiving PV (Fig. 5): however. the protective effect of endotoxin was still noticeable as the booster was repeated. As shown in the Table 2 . the effect of endotoxin on hyperglycemia was not as prompt as that of pertussigen. Tihis endotoxin of B. pc~r11r.s.\i.s is known to possess all the usual biologic components of enterobacterial endotoxins (2) and may act as an immunoregulator by altering the immune response in the host (5) . There is also new evidence that suggests phagocyte impotcr~ce may be caused by an invasive bacterial adenyl cyclase of 8. pc~rflr.s.sis (4) . This may further ameliorate the inflammatory process in the islets by reducing the biochemic outburst of 1.he inflammatory cells. such as macrophages.
The results of the study on the prevention of experimental (I 1.
15) or human diabetes (3. 6. 12. 2 1. 23). such as ours and others offer an opportunity to re-assess the current management of diabetes in man. Insulin and other supportive care have undoubtedly decreased the mortality caused by IDD as a result of acute ketoacidosis in new patients: however. the prevention of morbidity and mortality resulting from various complications ofdiabetes occurring in later years has not been satisfactory. This grows out of the fact that the pathogenesis of IDD in man is complex and poorly understood. In some patients there are indications for early intervention to halt the disease process and this early intervention is probably more justified in patients whose early disease process are accompanied with immunologic injury to [jcells. There arc already reports of attempts to halt the disease by employing various immunosuppressants in new patients (3. 6.
13. 21. 33). The resi~lts of those studies were still too early to assess but more efforts are likely to be attempted as long as Lhc incidence of IDD in man remains unchanged. Future stuclies focused on the prevention of diabetes should consider: I ) de\~el-oping meaningful parameters to accurately predict the stage of the disease. thus allowing us to determine optimal time for intervention. and 2) evaluating the efficacy of using biologic products such as those produced by 8. 
